Manchester Capital Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $34K | Buy |
425
+27
| +7% | +$2.23K | ﹤0.01% | 564 |
|
|
2025
Q4 | $33.9K | Sell |
398
-95
| -19% | -$7.8K | ﹤0.01% | 557 |
|
|
2025
Q3 | $38.3K | Sell |
493
-13
| -3% | -$1.02K | 0.01% | 620 |
|
|
2025
Q2 | $39.6K | Sell |
506
-4
| -0.8% | -$298 | 0.01% | 604 |
|
|
2025
Q1 | $37K | Buy |
510
+20
| +4% | +$1.43K | ﹤0.01% | 606 |
|
|
2024
Q4 | $36.3K | Buy |
490
+53
| +12% | +$3.71K | ﹤0.01% | 606 |
|
|
2024
Q3 | $28.8K | Buy |
437
+203
| +87% | +$14.7K | ﹤0.01% | 644 |
|
|
2024
Q2 | $21.6K | Sell |
234
-15
| -6% | -$1.33K | ﹤0.01% | 649 |
|
|
2024
Q1 | $23.8K | Buy |
249
+162
| +186% | +$13.6K | ﹤0.01% | 542 |
|
|
2023
Q4 | $6.63K | Buy |
87
+17
| +24% | +$1.18K | ﹤0.01% | 662 |
|
|
2023
Q3 | $4.85K | Hold |
70
| – | – | ﹤0.01% | 649 |
|
|
2023
Q2 | $6.6K | Buy |
70
+10
| +17% | +$869 | ﹤0.01% | 588 |
|
|
2023
Q1 | $4.96K | Hold |
60
| – | – | ﹤0.01% | 620 |
|
|
2022
Q4 | $4.48K | Hold |
60
| – | – | ﹤0.01% | 541 |
|
|
2022
Q3 | $5K | Hold |
60
| – | – | ﹤0.01% | 512 |
|
|
2022
Q2 | $6K | Hold |
60
| – | – | ﹤0.01% | 534 |
|
|
2022
Q1 | $7K | Hold |
60
| – | – | ﹤0.01% | 592 |
|
|
2021
Q4 | $8K | Hold |
60
| – | – | ﹤0.01% | 589 |
|
|
2021
Q3 | $7K | Sell |
60
-66
| -52% | -$7.53K | ﹤0.01% | 628 |
|
|
2021
Q2 | $13K | Buy |
126
+66
| +110% | +$6.22K | ﹤0.01% | 479 |
|
|
2021
Q1 | $5K | Sell |
60
-23
| -28% | -$1.94K | ﹤0.01% | 533 |
|
|
2020
Q4 | $8K | Buy |
83
+54
| +186% | +$4.48K | ﹤0.01% | 493 |
|
|
2020
Q3 | $2K | Buy |
+29
| New | +$2.26K | ﹤0.01% | 475 |
|
|
2018
Q2 | – | Sell |
-18
| Closed | -$1K | – | 552 |
|
|
2018
Q1 | $1K | Buy |
+18
| New | +$782 | ﹤0.01% | 552 |
|
|
2016
Q1 | – | Sell |
-540
| Closed | -$14K | – | 620 |
|
|
2015
Q4 | $14K | Hold |
540
| – | – | ﹤0.01% | 589 |
|
|
2015
Q3 | $13K | Hold |
540
| – | – | ﹤0.01% | 574 |
|
|
2015
Q2 | $13K | Hold |
540
| – | – | ﹤0.01% | 499 |
|
|
2015
Q1 | $12K | Sell |
540
-90
| -14% | -$2.02K | ﹤0.01% | 487 |
|
|
2014
Q4 | $13K | Hold |
630
| – | – | ﹤0.01% | 937 |
|
|
2014
Q3 | $11K | Hold |
630
| – | – | ﹤0.01% | 941 |
|
|
2014
Q2 | $9K | Hold |
630
| – | – | ﹤0.01% | 954 |
|
|
2014
Q1 | $8K | Buy |
630
+450
| +250% | +$5.19K | ﹤0.01% | 873 |
|
|
2013
Q4 | $2K | Sell |
180
-564
| -76% | -$6.36K | ﹤0.01% | 884 |
|
|
2013
Q3 | $9K | Buy |
+744
| New | +$8.7K | ﹤0.01% | 833 |
|
Other funds holding EW
VCM
VPM
Manchester Capital Management's EW Position: Q1 2026 in Review
Manchester Capital Management increased its Edwards Lifesciences (EW) stake by 6.8% in Q1 2026, buying an estimated $2.23K and bringing the position to 425 shares worth $34K. The position accounts for ﹤0.01% of the portfolio, ranked #564.
Manchester Capital Management first reported a position in EW in Q3 2013 and has held it in 34 quarters since. The position peaked at $39.6K in Q2 2025. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Manchester Capital Management held 425 shares of Edwards Lifesciences worth $34K as of Q1 2026.
- Manchester Capital Management bought 27 Edwards Lifesciences shares in Q1 2026, an estimated $2.23K.
- Edwards Lifesciences made up ﹤0.01% of Manchester Capital Management's portfolio in Q1 2026, its #564 holding.
- Manchester Capital Management first reported a position in Edwards Lifesciences in Q3 2013 and has held it in 34 quarters since.
- Manchester Capital Management's Edwards Lifesciences position peaked at $39.6K in Q2 2025.
- 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Manchester Capital Management's 13F filing for Q1 2026, filed 11 May 2026.